基石药业-B：截至二零二五年六月三十日止六个月中期业绩公告

CStone Pharmaceuticals 2616 •254.2204.880.5%49.420.217.911.3(1)(2)Istituto GentiliGentili •82.160.1142.2 •66.239.0105.2•46.73.243.5•62.827.135.7•270.215.7285.9•652.8 •71.031.1102.1 •109.632.477.2•265.110.8275.9 •®PD-L1 IVNSCLCEMAIIINSCLCCRTIIINSCLCPD-(L)1 SteinCares10LATAMGentili2360 •GEMSTONE-303[GC/GEJC]PFSOSJAMA (GEMSTONE-302IVNSCLC•(Lancet Oncology) •ESMONSCLCNSCLC[I, A] •®(RET) ®100mg •®KIT/PDGFRA ®300mg100mg® •CS5001ROR1 ADC Ib CS5001CS5001R-CHOP++++BDLBCLCS5001SOCDLBCLDLTIICS5001 •CS2009PD-1/VEGF/CTLA-4 I/II CS2009I/IIIIIaPKPDESMO BICI/O Ia530mg/kgDLTCS2009IIRP2D1-30mg/kgCS2009PKPDCS2009PD-1CTLA-4TVEGFAPD-(L)1 •NofazinlimabPD-1 CS1003-305 CS1003-305IIInofazinlimabOSPFSORR INDADC ADCFIC/BIC2.0 ADC2.0ADCCS5007[EGFR]3[HER3]ADCCS50052[SSTR2]ADCCS5008δ3[DLL3]SSTR2ADCCS5006β4[ITGB4]ADCCS5009B7H3/PD-L1ADC A A C RCS2009PD-1/VEGF/CTLA-4CS2011EGFR/HER3CS5007EGFR/HER3ADCCS5006(ITGB4ADC)CS5005(SSTR2 ADC) CS2013B[BAFF][APRIL]CS2015OX40[OX40L][TSLP]FIC/BICIND • CS5001(ROR1 ADC)CS2009PD-1/VEGF/CTLA-4 • ®® • ADCESMOASH 18A.08(3) 26164916NDAADC16 •®PD-L1 PD-L1OmniRat®G4(IgG4) •IVNSCLC(EGFR)(ALK)NSCLCNSCLC •IIINSCLCIIINSCLC NK/T •ESCCESCC •G/GEJPD-L1CPS≥5G/GEJ ECMHRA®EGFRALK1ROS1RETNSCLCEMAIIINSCLCIIIIVNSCLC EwopharmaPharmalinkSteinCares10Gentili2360Gentili1.92550%Gentili •ESMO®NSCLC[I, A] •GEMSTONE-303G/GEJCPS≥5PFSOSGEMSTONE-302• ®RET ®RETRETNSCLCRETNSCLCRETMTCRETTCRETNSCLCTFDARETNSCLCRETTC ®®® ®100 mg ®11NSCLCTC®CSCONSCLCRET®RETNSCLC®IVRETNSCLCCSCO •®KIT/PDGFRA 11®KIT/PDGFRAPDGFRA18PDGFRA D842VGIST®TFDAPDGFRA D842VGIST ® ®®PDGFRA18PDGFRA D842VGIST ®CSCO CS5001LCB71 ROR1 ADCIb •CS5001ROR1ADCCS5001pyrrolobenzodiazepinePBD(Payload)(linker)CS5001PBDPBDPBDCS5001CS5001CS5001(DAR)CS5001ROR1 ADC •CS5001Ia/IbIbIIIbCS5001DLBCL CS5001R-CHOPDLBCLCS5001DLBCLCS5001ROR1CS5001 CS2009PD-1/VEGF/CTLA-4I/OI/II •CS20092.0PD-1/VEGF/CTLA-4PD-1CTLA-4VEGFACS2009TPD-1CTLA-4TCTLA-4TMETMEVEGFACS2009PD-1CTLA-4 •CS2009I/IIII100 Ia30SMCDLTRP2D130IbII CS2009PKPDCS2009PD-1CTLA-4TVEGFAPD-(L)1 IaPKPDESMO CS1002SHR-8068CTLA-4III •CS1002/SHR-8068CS1002 •CS1002/SHR-8068II/IIICS1002/SHR-8068NSCLCIIICS1002/SHR-8068HCC •CS1002/SHR-8068CS1002/SHR-8068CRCIIIND NofazinlimabCS1003PD-1 •CS1003-305III74PD-1nofazinlimab(CS1003)LENVIMA®HCCOSBICRPFSORR •nofazinlimabOSPFSORRnofazinlimabPD-(L)1 IND ADC •ADCADCβ A D CA D C2 . 0A D CC S 5 0 0 5 ( S S T R 2A D C )C S 5 0 0 8D L L 3 & S S T R 2A D CCS5006(ITGB4ADC)CS5007EGFR&HER3ADCCS5009B7H3/PD-L1ADC •ADC CS5007EGFR/HER3ADCCS5007EGFR/HER3(CS2011)βexatecanCS5007EGFRHER3EGFRHER3CS5007CS5007NSCLCSCCHN CRC CS5005(SSTR2 ADC)CS5008SSTR2/DLL3ADCCS5005SSTR2βIexatecanNENSCLCSSTR2CS5008DLL3/SSTR2ADCNENSCLCSSTR2DLL3CS5008 CS5006(ITGB4ADC)CS5006I T G B4A D CI T G B4α6( I T G A6)(α6β4 )N S C L CSCCHNCRC • CS2013BAFF/APRILCS2013BB A F FAPRILCS2013SLERAIgAIgANB CS2015OX40L/TSLPCS2015OX40LTSLPTh2ADCOPD 18A.08(3) EwopharmaPharmalinkSteinCaresGentili ®® PD-L1®Ewopharma18PharmalinkMENASteinCaresGentili 6(270,183)15,699 269(11) (269,914)15,688 8(0.21)0.01 1. 34 2. 21 3. 26,942232,10622,50922,05949,451254,165 4. 5. 6. 7. 8. 1,314,1391,275,512 9. 60 24,92348,6881,827–35,78635,24162,53683,929 060619090 090 0303160619090 11. 4.72100,000,0006.83%467.28425.79 254.2204.880.5%49.420.217.911.3(1)(2)Gentili 82.160.1142.2 14.85.59.3 12.98.34.6 66.239.0105.215.435.951.3 46.73.243.55.32.72.6 62.827.135.753.519.633.9 8.31.46.9 939218 12.00186,396,0000.0001146,294.762,090.16H.10 13.37115,928,803200.01,355.9 84,800,0004.6336.61%389.07338.12 2.93380,000,0005.86%232.29215.82 652.8672.9 100%73.6%73.9% 363,200,000 C1 C3 100,000,0004.726.83%467.28 13.379.30115,928,803200.01,355.9 2.9333.4580,000,0002.9048,000232.29215.82 •2410 (www.hkexnews.hk)(www.cstonepharma.com) D2 Kenneth Walton Hitchner III